Cyramza (ramucirumab) vs Jeselhy (pimitespib) ()
Cyramza (ramucirumab) vs Jeselhy (pimitespib) ()
Cyramza (ramucirumab) is a monoclonal antibody that works by inhibiting angiogenesis, the formation of new blood vessels, thereby starving tumors of the nutrients they need to grow; it is approved for use in certain types of lung, stomach, colon, and liver cancers. Jeselhy (pimitespib), on the other hand, is a heat shock protein 90 (Hsp90) inhibitor that interferes with the proper functioning of various proteins essential for cancer cell growth and survival; it is specifically approved in Japan for the treatment of unresectable, advanced, or recurrent gastrointestinal stromal tumors (GIST) that are resistant to standard treatments. The choice between Cyramza and Jeselhy would depend on the specific type of cancer a patient has, its stage, and the patient's overall health profile, as well as the recommendations of the oncologist based on the latest clinical evidence and guidelines.
Difference between Cyramza and Jeselhy (pimitespib)
| Metric | Cyramza (ramucirumab) | Jeselhy (pimitespib) |
|---|---|---|
| Generic name | ramucirumab | pimitespib |
| Indications | Gastric cancer, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma | Treatment of unresectable advanced or recurrent esophageal squamous cell carcinoma |
| Mechanism of action | Angiogenesis inhibitor by VEGFR-2 antagonism | Heat shock protein 90 (HSP90) inhibitor |
| Brand names | Cyramza | Jeselhy |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Hypertension, diarrhea, headache, hyponatremia | Not fully characterized, as it is a newer medication |
| Contraindications | Hypersensitivity to ramucirumab or any component of the formulation | Not fully characterized, as it is a newer medication |
| Drug class | Monoclonal antibody, antineoplastic agent | Antineoplastic agent, HSP90 inhibitor |
| Manufacturer | Eli Lilly and Company | Taiho Pharmaceutical |
Efficacy
Cyramza (Ramucirumab) Efficacy in Gastric Cancer
Cyramza (ramucirumab) is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in the growth of blood vessels that supply tumors with nutrients and oxygen. In the context of gastric cancer, Cyramza has been evaluated for its efficacy in several clinical trials. The drug has been shown to improve survival outcomes in patients with advanced gastric cancer when used as a single agent or in combination with chemotherapy. For instance, in the REGARD trial, ramucirumab monotherapy demonstrated a statistically significant improvement in overall survival compared to placebo in patients with advanced gastric cancer who had progressed after initial chemotherapy.
Furthermore, the RAINBOW trial evaluated the combination of ramucirumab with paclitaxel versus paclitaxel alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma following progression on first-line platinum- and fluoropyrimidine-containing chemotherapy. The study showed that the combination of ramucirumab and paclitaxel significantly improved overall survival and progression-free survival compared to paclitaxel alone. These findings have supported the use of Cyramza in the second-line treatment setting for patients with advanced gastric cancer.
Jeselhy (Pimitespib) Efficacy in Gastric Cancer
Jeselhy (pimitespib) is a newer therapeutic agent that functions as a heat shock protein 90 (HSP90) inhibitor. HSP90 is a molecular chaperone that is involved in the proper folding and function of many proteins, including those that promote tumor growth and survival. While Jeselhy has shown promise in preclinical models, its efficacy in gastric cancer is still under investigation, and there may be limited data from large-scale clinical trials available at this time. It is important to note that the use of Jeselhy in gastric cancer would be considered off-label unless specific clinical trials have demonstrated its efficacy and safety in this indication.
As of the current knowledge cutoff, there may not be extensive data on the efficacy of Jeselhy (pimitespib) in the treatment of gastric cancer. Any ongoing or completed clinical trials would provide valuable information regarding its potential benefits in this disease. It is essential for healthcare professionals to consult the latest clinical research and guidelines when considering the use of new medications like Jeselhy for off-label indications such as gastric cancer.
Regulatory Agency Approvals
Cyramza
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Jeselhy (pimitespib)
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Cyramza or Jeselhy (pimitespib) today
If Cyramza or Jeselhy (pimitespib) are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us